What investment strategy does ARCHIMED focus on?

ARCHIMED focuses on Growth, Buyout strategies in the private equity space.

How many portfolio companies does ARCHIMED have?

ARCHIMED has 36 active portfolio companies and 15 completed exits and 6 funds tracked on GP Intel.

Where is ARCHIMED headquartered?

ARCHIMED is headquartered in Lyon, France.

What is ARCHIMED's assets under management?

ARCHIMED manages approximately €9.0B in assets under management.

What sectors does ARCHIMED invest in?

ARCHIMED invests across Healthcare, Business Services, Software, Consumer.

Home/GPs/ARCHIMED

ARCHIMED

Lyon, France·Founded 2010·

Growth Equity Buyout

·archimed.group

ARCHIMED is a global private equity firm founded in 2014 and headquartered in Lyon, France, focused exclusively on healthcare industries. It manages around 8 billion across various funds and invests in profitable small and midsize…Read full bio

AUM

€9.0B

Funds

Portfolio

Exits

SectorsHealthcareBusiness ServicesSoftwareConsumer

Key facts

HQLyon, France

Founded2010

Websitearchimed.group

Recent exits

Ametris (ActiGraph)

HealthTech · 2026

CARSO

MedTech · 2025

DIESSE

MedTech · 2025

4.6xsample

Citieffe

MedTech · 2025

Showing 1 of 2 multiples · Unlock all on Pro

Coverage notes

About ARCHIMED

ARCHIMED is a French private equity firm exclusively dedicated to healthcare with €9.0 billion of assets under management as of December 2024, founded in 2014 and headquartered in Lyon with additional offices in Paris, London, New York, Milan and Munich. The firm is one of the few European private equity platforms focused entirely on healthcare verticals, providing depth of sector expertise across pharmaceuticals, medical technologies and life sciences services that generalist mid-cap funds cannot match.

Investment thesis

ARCHIMED targets European and selectively North American healthcare companies across MedTech, Pharma services, HealthTech, Biotech and broader healthcare services, deploying capital through dedicated flagship funds (MED Platform I, II and follow-on vintages) plus a Eureka small-cap programme for emerging healthcare companies. Equity ticket sizes typically range from €50 million to €300 million for the flagship strategy, with majority and significant minority equity positions held through five to seven year horizons. The healthcare sector-exclusive focus enables deep operational expertise, regulatory navigation and management team networks unique to medical-device, pharma and HealthTech businesses.

Recent activity

Recent realised exits include Ametris / ActiGraph (HealthTech, 2026), CARSO (MedTech, 2025), Citieffe (MedTech, 2025), DIESSE (MedTech, 2025), Ad-Tech Medical Instrument (MedTech, 2024) and Deallus (Pharma, 2024), demonstrating strong distribution momentum across the medical device and pharma services verticals. The platform tracks 6 funds, 36 active portfolio companies and 15 realised exits, with ongoing deployment from the latest flagship vintage across European and North American healthcare targets. Detailed buyer names and multiple data available on Pro at €49/month.